Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
Breast Cancer Research and Treatment
|
August 12, 2009
Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
Belinda E Kiely, Mark A Jenkins, Joanne M McKinley, et al.
Gynecologic Oncology
|
December 27, 2021
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)
Vanessa L Beesley, Tanya L Ross, Madeleine T King, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 11, 2017
Resisting RECIST-Uniformity Versus Clinical Validity
Michelle K Wilson, Michael L Friedlander, Stephanie Lheureux, et al.
The Oncologist
|
October 11, 2013
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study
Katrin M Sjoquist, Michael L Friedlander, Rachel L O'Connell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 22, 2014
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer
Madeleine T King, Martin R Stockler, Phyllis Butow, et al.
Journal of Translational Medicine
|
December 6, 2022
Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study
Kosar Hooshmand, David Goldstein, Hannah C Timmins, et al.
The Lancet. Oncology
|
August 2, 2005
What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Belinda Thewes, Bettina Meiser, Vlatka M Duric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 28, 2007
Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer
Sarah-Jane Dawson, Melanie A Price, Mark A Jenkins, et al.
Familial Cancer
|
June 14, 2005
Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort
Kelly-Anne Phillips, Phyllis N Butow, Ailsa E Stewart, et al.
Cancer
|
March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
Breast Cancer Research and Treatment
|
August 12, 2009
Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)
Belinda E Kiely, Mark A Jenkins, Joanne M McKinley, et al.
Gynecologic Oncology
|
December 27, 2021
Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)
Vanessa L Beesley, Tanya L Ross, Madeleine T King, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 11, 2017
Resisting RECIST-Uniformity Versus Clinical Validity
Michelle K Wilson, Michael L Friedlander, Stephanie Lheureux, et al.
The Oncologist
|
October 11, 2013
Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study
Katrin M Sjoquist, Michael L Friedlander, Rachel L O'Connell, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
May 22, 2014
Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer
Madeleine T King, Martin R Stockler, Phyllis Butow, et al.
Journal of Translational Medicine
|
December 6, 2022
Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study
Kosar Hooshmand, David Goldstein, Hannah C Timmins, et al.
The Lancet. Oncology
|
August 2, 2005
What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Belinda Thewes, Bettina Meiser, Vlatka M Duric, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 28, 2007
Cancer risk management practices of noncarriers within BRCA1/2 mutation positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer
Sarah-Jane Dawson, Melanie A Price, Mark A Jenkins, et al.
Familial Cancer
|
June 14, 2005
Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort
Kelly-Anne Phillips, Phyllis N Butow, Ailsa E Stewart, et al.
Cancer
|
March 19, 2021
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
Chee Khoon Lee, Michael L Friedlander, Angelina Tjokrowidjaja, et al.
Page
of 9